跳至主要内容
临床试验/NCT06572241
NCT06572241招募中不适用

Quality of Labour Epidural Analgesia With Intrathecal Morphine as a Component of Combined Spinal Epidural: a Double-blinded Randomized Control Trial

Samuel Lunenfeld Research Institute, Mount Sinai Hospital1 个研究点 分布在 1 个国家目标入组 182 人开始时间: 2024年11月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
182
试验地点
1
主要终点
Presence of breakthrough pain: questionnaire

研究概览

简要总结

Neuraxial analgesia has shown to be the gold standard for effective labor pain relief, offering numerous benefits including enhanced pain control and maternal satisfaction. The methods to achieve neuraxial analgesia include lumbar epidural (LE), and combined spinal epidural (CSE). While LE may not consistently provide optimal pain relief, leading to frequent maternal requests for supplemental analgesics, CSE presents a promising advancement. This is due to the rapid onset of pain relief from intrathecal components, complemented by the longer-lasting effects of epidural medications. Intrathecal drugs have demonstrated the ability to offer more symmetrical blockades compared to epidurally administered medications. Nonetheless, some clinicians remain cautious about CSE due to the potential for increased pain when transitioning from spinal to less effective epidural analgesia. Long-acting opioids like morphine in the intrathecal space may mitigate this problem by providing transitional analgesia to the laboring parturient.

The primary aim of this randomized controlled trial is to provide evidence of whether the addition of 100 mcg of morphine in the intrathecal (spinal) component of CSE reduces the rate of breakthrough pain during labor.

详细描述

The addition of morphine to a combination of bupivacaine and lipophilic opioids (fentanyl) for the spinal component of CSE for labor analgesia has been shown to increase the duration of analgesia. A meta-analysis by Al-Kazwini and coworkers suggests a possible beneficial prolonging effect of adding morphine to spinal analgesia, however, the authors concluded that more adequately powered randomized controlled trials (RCTs) are required to determine the benefits and harms of intrathecal morphine (ITM).

This prolonged duration of action of ITM may reduce the need for frequent top-ups, which could alleviate nursing and anesthesiologist workload and enhance maternal satisfaction. An RCT conducted by Vasudevan and coworkers has concluded that the addition of 100 mcg ITM along with bupivacaine and fentanyl reduced the incidence of breakthrough pain in labor. Another dose-finding study comparing 50 and 100 mcg of ITM as a component of CSE labor analgesia concluded that 100 mcg of ITM significantly lowers the local anesthetic consumption and shorter duration of the first stage of labor without any significant difference in adverse effects. The RCT by Vasudevan et al. had a small sample size, enrolled mixed parity patients, and utilized continuous infusion for labor analgesia maintenance.

Hence, the investigators plan to conduct adequately powered RCT enrolling only primigravidae patients, which tend to have more prolonged labor than multiparous and programmed intermittent epidural bolus (PIEB) with patient-controlled epidural analgesia (PCEA) will be used, which is a more contemporary labor maintenance technique.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Adult (≥18 years) term primiparous (≥37 weeks) patients with live singleton pregnancy
  • Patients who request labour analgesia and do not have any contraindications for neuraxial analgesia.
  • Less than or equal to 6 cm cervical dilation during the last vaginal examination.

排除标准

  • Patients who are expected to be discharged within 24 hours of delivery.
  • Patients with chronic pain conditions, opioid use disorder, pre-gestational diabetes, obstructive sleep apnea, morbid obesity (BMI >40 kg/m2), or fetal abnormalities.
  • Patients who have intramuscular morphine within 12 hours or fentanyl >200 mcg in the preceding 4 hours.
  • Participants will be excluded from further analysis in case of spinal analgesic failure
  • Participants will be excluded from further analysis if labour lasts less than 2 hours

研究组 & 干预措施

Morphine

Active Comparator

0.6 ml of 0.25% bupivacaine, fentanyl 10 mcg with morphine 100 mcg (total volume 1 ml) as intrathecal component of combined spinal epidural (CSE).

干预措施: Intrathecal morphine (Drug)

Placebo

Placebo Comparator

0.6 ml of 0.25% bupivacaine, fentanyl 10 mcg with normal saline 0.2 ml (total volume 1 ml) as intrathecal component of combined spinal epidural (CSE).

干预措施: Saline solution (placebo) (Other)

结局指标

主要结局

Presence of breakthrough pain: questionnaire

时间窗: 24 hours

The rate of breakthrough pain is defined as the ratio of the number of episodes of breakthrough pain during labour analgesia and the duration of epidural analgesia. An episode of breakthrough pain during labour analgesia was defined as subjective discomfort due to pain or pressure increasing during a contraction (rated as NRS ≥3/10), which was successfully treated with the manual administration of supplemental medications.

次要结局

  • Time to first episode of breakthrough pain in minutes(24 hours)
  • Epidural medication consumption (milliliters)(24 hours)
  • Epidural pump settings: questionnaire(24 hours)
  • Presence of fetal heart rate anomalies: questionnaire(24 hours)
  • Presence of Cesarean delivery: questionnaire(24 hours)
  • Analgesic consumption post-delivery: questionnaire(24 hours)
  • Presence of pruritis: questionnaire(24 hours)
  • Presence of nausea: questionnaire(24 hours)
  • Presence of vomiting: questionnaire(24 hours)
  • Presence of sedation: questionnaire(24 hours)
  • Presence of respiratory depression: questionnaire(24 hours)
  • Apgar score at 1 minute(1 minute)
  • Apgar score at 5 minutes(5 minutes)
  • Umbilical artery pH(24 hours)
  • Umbilical vein pH(24 hours)
  • Satisfaction: questionnaire(24 hours)
  • Obstetric Quality of Recovery-10 (ObsQoR-10) score 24 hours(24 hours)

研究者

发起方
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验